< Press Releases 2008–Present


9|17|07
Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis / MPM Bio IV NVS Strategic Fund L.P. invests $10 million in Radius


6|8|07
Radius Presents Positive Results from Phase 1B Clinical Trial of BA058 and Preclinical Study of RAD1901 at ENDO 2007


4|2|07
Radius Raises $57.5 Million in Second Private Financing Round


3|20|07
Radius Begins Phase 2 Clinical Trial of BA058 for Osteoporosis


1|2|07
Radius Appoints Nick Harvey Senior Vice President and CFO


8|7|06
Radius Licenses Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists


6|29|06
Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs


4|12|06
Radius Appoints Louis O’Dea Senior Vice President and Chief Medical Officer


12|13|05
Radius Announces Licensing Agreement for Ipsen Osteoporosis Proprietary Molecule BA058 / PTHrP Analog in Phase 1 Clinical Trials


11|12|04
Nuvios* Names Dr. Christopher Glass to Scientific Advisory Board


10|4|04
Nuvios* Names C. Richard Lyttle President and CEO

*Name changed to Radius effective December 2005

© 2012 Radius Health, Inc.   |   Privacy Policy   |   Home   |   Contact

201 Broadway, 6th Floor, Cambridge, MA 02139
Tel: (617) 551-4700  |  Fax: (617) 551-4701